Literature DB >> 30664736

A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.

Stephen J Freedland1,2, Lauren Howard3, Jenifer Allen4, Jordan Smith5, Jennifer Stout6, William Aronson7,8, Brant A Inman6, Andrew J Armstrong9, Daniel George6, Eric Westman10, Pao-Hwa Lin5.   

Abstract

PURPOSE: The objective of this study was to test a low-carbohydrate diet (LCD) plus walking to reduce androgen deprivation therapy (ADT)-induced metabolic disturbances.
MATERIALS AND METHODS: This randomized multi-center trial of prostate cancer (PCa) patients initiating ADT was designed to compare an LCD (≤20g carbohydrate/day) plus walking (≥30 min for ≥5 days/week) intervention vs. control advised to maintain usual diet and exercise patterns. Primary outcome was change in insulin resistance by homeostatic model assessment at 6 months. To detect 20% reduction in insulin resistance, 100 men were required. The study was stopped early after randomizing 42 men due to slow accrual. Secondary outcomes included weight, body composition, lipids, and prostate-specific antigen (PSA). Changes from baseline were compared between arms using rank-sum tests.
RESULTS: At 6 months, LCD/walking reduced insulin resistance by 4% vs. 36% increase in control (p = 0.13). At 3 months, vs. control, LCD/walking arm significantly lost weight (7.8kg; p<0.001), improved insulin resistance (↑36%; p = 0.015), hemoglobin A1c (↓3.3%; p = 0.01), high-density lipoprotein (HDL) (↑13%; p = 0.004), and triglyceride (↓37%; p = 0.036). At 6 months, weight loss (10.6kg; p<0.001) and HDL (↑27%; p = 0.003) remained significant. LCD/walking preserved total body bone mineral count (p = 0.025), reduced fat mass (p = 0.002), lean mass (p = 0.036), and percent body fat (p = 0.004). There were no differences in PSA. Limitations include the effect of LCD, weight loss vs. walking instruction are indistinguishable, and small sample size.
CONCLUSIONS: In an underpowered study, LCD/walking did not improve insulin sensitivity at 6 months. Given most secondary outcomes were improved at 3 months with some remaining improved at 6 months and a secondary analysis showed that LCD/walking reduced insulin resistance over the study, supporting future larger studies of LCD/walking intervention to reduce ADT-induced disturbances.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30664736     DOI: 10.1038/s41391-019-0126-5

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  2 in total

1.  Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer.

Authors:  Ithaar H Derweesh; Christopher J Diblasio; Matt C Kincade; John B Malcolm; Kimberly D Lamar; Anthony L Patterson; Abbas E Kitabchi; Robert W Wake
Journal:  BJU Int       Date:  2007-09-14       Impact factor: 5.588

Review 2.  Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes.

Authors:  Hamed Ahmadi; Siamak Daneshmand
Journal:  Patient Relat Outcome Meas       Date:  2014-07-05
  2 in total
  17 in total

Review 1.  Diet and lifestyle considerations for patients with prostate cancer.

Authors:  Kyle B Zuniga; June M Chan; Charles J Ryan; Stacey A Kenfield
Journal:  Urol Oncol       Date:  2019-07-18       Impact factor: 3.498

2.  Efficacy of Low-Carbohydrate Ketogenic Diet as an Adjuvant Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Ya-Feng Yang; Preety Babychen Mattamel; Tanya Joseph; Jian Huang; Qian Chen; Babatunde O Akinwunmi; Casper J P Zhang; Wai-Kit Ming
Journal:  Nutrients       Date:  2021-04-21       Impact factor: 5.717

3.  The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer.

Authors:  Jen-Tsan Chi; Pao-Hwa Lin; Vladimir Tolstikov; Taofik Oyekunle; Gloria C G Alvarado; Adela Ramirez-Torres; Emily Y Chen; Valerie Bussberg; Bo Chi; Bennett Greenwood; Rangaprasad Sarangarajan; Niven R Narain; Michael A Kiebish; Stephen J Freedland
Journal:  Prostate       Date:  2021-05-05       Impact factor: 4.012

4.  Optimising weight-loss interventions in cancer patients-A systematic review and network meta-analysis.

Authors:  Nathalie LeVasseur; Wei Cheng; Sasha Mazzarello; Mark Clemons; Lisa Vandermeer; Lee Jones; Anil Abraham Joy; Pauline Barbeau; Dianna Wolfe; Nadera Ahmadzai; Mona Hersi; Carol Stober; Risa Shorr; John Hilton; Brian Hutton
Journal:  PLoS One       Date:  2021-02-04       Impact factor: 3.240

5.  Protocol for a feasibility and early efficacy study of the Comprehensive Lifestyle Improvement Program for Prostate Cancer-2 (CLIPP2).

Authors:  A M Algotar; R Kumar; H M Babiker; S T Dougherty; C H Hsu; H-H Chow; T E Smith; D G Marrero; K S Courneya; I Abraham; J A Ligibel; C A Thomson
Journal:  Contemp Clin Trials Commun       Date:  2021-01-13

Review 6.  Effects of Combined Exercise and Low Carbohydrate Ketogenic Diet Interventions on Waist Circumference and Triglycerides in Overweight and Obese Individuals: A Systematic Review and Meta-Analysis.

Authors:  Hyun Suk Lee; Junga Lee
Journal:  Int J Environ Res Public Health       Date:  2021-01-19       Impact factor: 3.390

Review 7.  Dietary Factors and Supplements Influencing Prostate Specific-Antigen (PSA) Concentrations in Men with Prostate Cancer and Increased Cancer Risk: An Evidence Analysis Review Based on Randomized Controlled Trials.

Authors:  Maria G Grammatikopoulou; Konstantinos Gkiouras; Stefanos Τ Papageorgiou; Ioannis Myrogiannis; Ioannis Mykoniatis; Theodora Papamitsou; Dimitrios P Bogdanos; Dimitrios G Goulis
Journal:  Nutrients       Date:  2020-09-29       Impact factor: 5.717

8.  Feasibility of an intervention for men on androgen deprivation therapy: A research protocol.

Authors:  Alana Manson; Jamie Myers; Sandra Billinger; Jaimie Ward; William Parker; Jill Hamilton-Reeves; Carrie Michel; Sally L Maliski
Journal:  Res Nurs Health       Date:  2019-08-07       Impact factor: 2.228

9.  Metabolomic effects of androgen deprivation therapy treatment for prostate cancer.

Authors:  Jen-Tsan Chi; Pao-Hwa Lin; Vladimir Tolstikov; Taofik Oyekunle; Emily Y Chen; Valerie Bussberg; Bennett Greenwood; Rangaprasad Sarangarajan; Niven R Narain; Michael A Kiebish; Stephen J Freedland
Journal:  Cancer Med       Date:  2020-03-31       Impact factor: 4.452

10.  Weight Loss for Obese Prostate Cancer Patients on Androgen Deprivation Therapy.

Authors:  Rebekah L Wilson; Robert U Newton; Dennis R Taaffe; Nicolas H Hart; Philippa Lyons-Wall; Daniel A Galvão
Journal:  Med Sci Sports Exerc       Date:  2021-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.